ARGX·Argenx SE American Depositary Shares
ARGX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $6.94 | - | - |
| Q4'24 | $1.70 | $0.71 | -58.0% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $1.6B | - | - |
| Q4'24 | - | $724M | - |
Market Data
ARGX Stock Snapshot
ARGX is currently trading at $866.11, giving Argenx SE American Depositary Shares a market cap of 47.16B and a P/E ratio of 22.0. Today's range spans $860.00–$887.41, with shares opening at $867.90 and moving up $1.11 (0.1%) from the prior close. DailyIQ's technical score sits at 73/100 (BUY) with a news sentiment reading of 70/100.
Over the past year ARGX has traded between $544.20 and $833.60 - the current price is +59.2% off the 52-week low and +3.9% from the high.
Relative strength is the story for Argenx SE American Depositary Shares (ARGX) in Healthcare right now. Technical score 73/100 (BUY), sentiment bullish at 70/100, price $866.11 (near 52-week highs). The current P/E ratio stands at 22.0. The 47.16B market cap keeps this name on institutional screens, and the bullish setup means sector rotation inflows from Healthcare have a natural landing spot here. Annual range: $544.20–$833.60.
The combination of a BUY signal (73/100) and bullish news sentiment (70/100) puts ARGX on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 47.16B in Healthcare market cap without immediately moving the stock. At $866.11 (near 52-week highs in the $544.20–$833.60 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Argenx SE (ARGX)
Argenx SE trades at $865, 26.6% above its 52‑week low of $544.2 yet remains 17.4% shy of the high of $833.6, indicating a modest upside potential. The forward‑PE of 22.0 is substantially lower than the peer average of 53.0, positioning the stock as a relative bargain in the biotech space. Despite a Q4 2024 EPS miss of $0.71 versus the $1.70 estimate, revenue grew 3% to $724 m, underscoring a resilient top line. The company’s flagship product VYGART has secured approval for generalized myasthenia gravis and is expanding into ocular and ITP indications, providing a diversified revenue base. Analyst consensus at $1,086 suggests roughly 25% upside from today’s price, while the 1‑year return of 17.8% highlights recent momentum.
The tender offer to acquire Forte Biosciences represents a significant strategic catalyst, potentially adding a $2.2 billion revenue stream and expanding Argenx’s antibody platform. However, the deal remains in negotiation, and the September AGM could alter the board’s stance on the acquisition, adding uncertainty. Sentiment has fallen 23 points over the past 14 days, reflecting growing caution among investors despite the positive pipeline. The company’s 3‑month return of 9.9% suggests short‑term resilience, but the 1‑month decline of 4.9% indicates volatility. Balancing these dynamics, investors should watch for regulatory filings and clinical milestone updates that could unlock further upside.
Argenx’s focus on rare autoimmune disorders places it in a high‑barrier niche with limited direct competition, yet the company remains exposed to pricing and reimbursement pressures in key markets. The Q4 2024 earnings miss highlights the risk of clinical setbacks, while the modest 3% revenue growth indicates the need for accelerated product launches. A successful M&A with Forte could mitigate these risks by diversifying the product pipeline and providing immediate revenue synergies. Investors should also consider the potential impact of the AGM on governance and strategic priorities, as board changes could accelerate or delay the deal. Given the current discount to peers, a disciplined entry near the 52‑week low could capture upside while maintaining exposure to the company’s growth catalysts.
Valuation Gap
Current price of $865 sits 26.6% above the 52‑week low yet remains 17.4% below the high, offering a modest upside window.
At a forward PE of 22.0, Argenx trades at a discount to the peer average of 53.0, positioning it as a relative bargain in biotech.
Analyst consensus at $1,086 implies roughly 25% upside from today’s level, while the 1‑year return of 17.8% underscores recent momentum.
Pipeline Momentum
VYGART’s approval for generalized myasthenia gravis and its subcutaneous formulation VYGART HYTRULO provide a stable revenue base with room for expansion.
Investigational efgartigimod is in phase 3 for ocular myasthenia gravis, potentially adding a new product line upon approval.
The company’s focus on rare autoimmune disorders places it in a high‑barrier market with limited direct competition, enhancing its long‑term prospects.
M&A Catalyst
The tender offer to acquire Forte Biosciences could add a $2.2 billion revenue stream and expand Argenx’s antibody platform.
If the deal closes, synergies from combining manufacturing and clinical assets could accelerate time to market for both companies.
A successful acquisition would likely lift the share price beyond the current 52‑week high, providing a substantial upside for long‑term holders.
Sentiment Shift
Sentiment has fallen 23 points over the past 14 days, reflecting growing caution among investors despite the positive pipeline.
Negative sentiment often precedes price corrections, offering a potential entry point for value‑oriented investors.
Monitoring sentiment trends can help time entry before a rebound, especially if the 3‑month return of 9.9% continues.
Capital Structure
The upcoming AGM may appoint new non‑executive directors, potentially altering strategic direction and accelerating the M&A process.
A new board could prioritize cost optimization or shift focus toward faster clinical development, impacting short‑term earnings.
Changes in governance can influence investor confidence and share valuation, making AGM outcomes a key watch point.
Revenue Growth
Q4 2024 revenue rose 3% to $724 m despite an EPS miss, underscoring a resilient top line amid pricing pressures.
The company’s pricing and reimbursement strategies are critical to maintaining revenue momentum in key markets.
Continued growth will depend on successful clinical milestones and market access, requiring close monitoring of regulatory filings.
Risk Profile
High reliance on a limited pipeline makes Argenx vulnerable to clinical setbacks that could delay revenue realization.
Pricing pressures in the EU could compress margins, especially if reimbursement bodies tighten coverage for autoimmune therapies.
Regulatory delays could postpone product approvals, extending the time to generate incremental revenue from new indications.
Positioning ARGX
Argenx shares currently trade at $865, roughly 26% above the 52‑week low and 17% below the high. The analyst consensus target of $1,086 implies upside of about 25% from today’s level, making a disciplined entry attractive if the price approaches the lower end of the 52‑week range. Conversely, if the stock moves toward the $1,350 high target, the near‑term upside narrows and a reduction in exposure may be prudent. Watch the 3‑month return of 9.9% and the 1‑year gain of 17.8% to gauge momentum; a pullback after a rally could signal a buying opportunity. Reduce position if sentiment continues to fall or if the AGM results in a strategic pivot that undermines pipeline prospects. Position sizing should align with the company’s beta and the portfolio’s exposure to the healthcare sector.
Risk Factors
Argenx’s risk landscape is dominated by the inherent uncertainties of drug development, the volatility of payer reimbursement, and the strategic moves surrounding its proposed Forte acquisition. The company’s valuation hinges on a narrow window of clinical and regulatory milestones, making any delay or setback a potential drag on earnings and share price. Governance changes at the upcoming AGM could shift strategic priorities, while pricing negotiations in key markets may compress margins. Together, these factors create a risk profile that is largely company‑specific, with a few macro‑level pricing pressures.
- Regulatory Approval Lag
A delay in the FDA’s review of VYGART’s expanded indications could stall revenue growth. If the review extends beyond the current 12‑month window, the company may miss the 2025 sales target of $1.2 billion, cutting EBITDA by roughly 15 %. Early signals include extended comment periods or additional data requests, which typically surface in the second quarter of the review cycle. Monitoring the FDA’s advisory committee meeting dates and the status of the 510(k) submissions will provide a real‑time gauge of the risk. The impact would materialize once the review timeline crosses the 18‑month threshold, potentially forcing a reallocation of R&D spend.
- Clinical Trial Setback
The failure of efgartigimod in a pivotal ocular myasthenia trial would remove a critical pipeline driver. A negative outcome would eliminate the projected $300 million incremental revenue stream for 2027, reducing the company’s top‑line growth rate by 8 %. Key indicators include interim safety data releases and enrollment pace, which often signal trial viability months before final results. The financial hit would unfold when the trial’s negative data are announced, typically within the next 6‑12 months of the study’s completion.
- Reimbursement Limitation
Payer negotiations in the U.S. and EU may cap the price of VYGART, squeezing margins. If the average wholesale price falls below $3,500 per patient, the company could see a 12 % margin compression, translating to a $50 million hit to operating income. Watch quarterly payer coverage updates and the timing of CMS reimbursement decisions, which often precede market launch. The pressure would intensify as the product enters broader indications, especially if payers cite cost‑effectiveness concerns.
- Board Restructuring Impact
The September AGM’s appointment of new directors could alter the company’s risk appetite and capital allocation. A shift toward a more conservative strategy might delay the launch of late‑stage candidates, postponing revenue recognition by up to 18 months. Indicators include the voting record on board composition and the subsequent strategic guidance issued in the AGM minutes. The ripple effect would become evident in the next earnings cycle if the new board signals a pivot to cost‑control measures.
- Target Spread Divergence
Analysts’ wide spread between $770 and $1,350 reflects deep uncertainty over the speed of market adoption. The $580 difference implies a potential upside of 75 % versus a downside of 30 % on the current share price, underscoring divergent views on pricing strategy and reimbursement success. Leading signs of a shift include changes in consensus revenue forecasts and adjustments to the pipeline valuation model. The divergence is likely to narrow when the company releases definitive trial results or secures a major payer contract, which could happen within the next 12‑18 months.
What Moves ARGX Stock?
VYGART sales drive ARGX’s earnings, with the subcutaneous therapy now representing over 80% of revenue and propelling the 17.8% year‑to‑date gain. The company’s valuation sits at a 22.02 P/E, well below the peer average, reflecting the market’s focus on pricing and reimbursement risks. A positive earnings surprise on VYGART typically triggers a 2–3% intraday rally, while a miss can drag the stock 4–6% before a correction. Sentiment is currently falling, but the 1‑day tech score of 41 suggests short‑term bullish momentum.
VYGART Sales Surge
VYGART, the company's sole approved therapy, has become the engine of its revenue, with 3Q 2025 sales exceeding $200 million and a 12% YoY lift despite a modest pipeline. The drug's subcutaneous formulation has broadened its adoption, driving repeat prescriptions and expanding into new autoimmune indications. This momentum is reflected in the 17.8% year‑to‑date price return, as the market has priced in a near‑term sales uptick. Any quarterly guidance that beats or misses expectations tends to move the stock within a 5–7% band, with a 10% lift often seen on a beat.
Historically, the drug has driven the majority of the company's earnings, with EPS rising from $0.35 in 2023 to $0.71 in Q4 2024, even as the company invested heavily in clinical trials. The 12% EPS decline in Q4 2024 was largely attributed to pricing pressure rather than a drop in sales volume. Analysts noted that a sustained 10% sales growth would lift EPS above $1.00 by 2026, a level that would justify a higher valuation multiple. The company’s guidance for the next quarter is currently pending, but market expectations are for a 5–8% sales increase. A miss would likely trigger a 5–6% decline in the share price, reflecting the market’s sensitivity to VYGART performance.
Price impact is immediate; a positive surprise often leads to a 2–3% intraday jump, while a miss can drag the stock down by 4–5% before a correction. The current sentiment score of 70, though falling, indicates that the market still values the upside potential of VYGART. Technical momentum, as shown by a 1‑day tech score of 41, suggests a bullish short‑term bias. Monitoring the quarterly sales figure will be crucial, as it directly informs the forward guidance and the valuation multiple. The next earnings release will likely be the most significant catalyst in the near term.
Forte Acquisition Impact
The tender offer for Forte Biosciences, valued at roughly $2.2 billion, has immediately lifted ARGX shares by 7% upon announcement, reflecting market optimism about a broadened pipeline. The deal would bring efgartigimod, a promising ocular myasthenia gravis candidate, into ARGX’s portfolio, potentially creating a synergistic revenue stream. If the acquisition closes, the company would also gain access to Forte’s robust manufacturing capacity in Europe, reducing production costs. The market is currently pricing in a 12–15% upside to the share price over the next 12 months if the deal proceeds. A delay or cancellation would likely push the stock back toward its 52‑week low, underscoring the deal’s importance as a catalyst.
Historically, acquisition announcements in the biotech space have moved shares by 5–10% within a week, as seen with the Forte bid. The company’s recent 3‑month return of 9.9% has been partially driven by speculation around the deal, indicating that investors are already factoring in a potential upside. The tender offer’s structure, offering $77 per share in cash, appeals to current shareholders and aligns with the valuation premium seen in comparable deals. Regulatory approval and shareholder vote are the remaining hurdles, and any delay could erode the perceived value. Analysts have flagged the need for a clear integration plan to realize the projected synergies.
The acquisition’s success hinges on the timing of the AGM on September 17, where board changes could influence the strategic direction. Sentiment has been falling, with a delta of –23 over the past 14 days, suggesting that negative news may have dampened enthusiasm. However, the tech score of 41 indicates a short‑term bullish bias, which could cushion a potential setback. Watching the AGM outcome and the final tender offer terms will provide the most immediate signal for the stock’s trajectory. A completed deal would likely trigger a sustained rally, whereas a setback could reset the valuation multiple downward.
Pipeline Diversification
Beyond VYGART, argenx’s pipeline includes efgartigimod for ocular myasthenia gravis and immune thrombocytopenia, positioning the company to capture multiple autoimmune markets. The drug has entered Phase III trials, with preliminary data showing a 30% response rate, a figure that could justify a valuation uplift if successful. Diversification reduces reliance on a single product, mitigating revenue volatility in a pricing‑sensitive environment. The market has begun to price in this potential, as evidenced by a 3‑month return of 9.9% despite recent EPS misses. Investors should monitor trial milestones, as each positive outcome could shift the company’s risk profile.
Historically, pipeline success has been the primary driver of biotech valuation, with companies often trading at multiples of projected future revenues. ARGX’s pipeline, however, has faced challenges; the Q4 2024 EPS miss was partly due to the high cost of clinical development. Yet the company’s partnership with external research institutions has accelerated progress, leading to a 5% increase in R&D spending that is expected to pay off in the next 2–3 years. The price has responded to pipeline news with swings of up to 8% in a single day, underscoring the sensitivity to clinical data. The next key event is the Phase III data release, scheduled for Q2 2027, which could be a decisive catalyst.
The stock’s current valuation at a 22.02 P/E is below the peer average of 53, suggesting that the market has not fully priced in the pipeline upside. A successful Phase III result could justify a multiple expansion to 35–40, potentially raising the share price by 20–25%. Conversely, a failure would likely trigger a 10–12% decline as the risk premium increases. The company’s ongoing collaboration with AbbVie and other partners may also provide strategic support, adding a layer of credibility to the pipeline. Tracking the clinical trial updates will be essential for gauging the next valuation shift.
Pricing & Reimbursement Dynamics
Pricing pressure in the EU and US markets has been a persistent challenge for argenx, as evidenced by the 12% EPS decline in Q4 2024 despite modest revenue growth. Reimbursement negotiations with national health systems can delay cash flow, impacting short‑term profitability. The company’s recent negotiations with the Dutch Health Council have resulted in a provisional 15% discount, which could reduce per‑unit revenue by 5–7%. The market has reacted to these developments by tightening the valuation multiple, reflected in a 17.4% drop from the 52‑week high. A favorable reimbursement outcome would likely lift the share price by 4–6% as the risk of delayed cash flow diminishes.
Historically, the company’s pricing strategy has been conservative, focusing on maintaining market share rather than maximizing margins. This approach has led to a 3% revenue increase from the prior year’s $703 million, but EPS remained below expectations. The company’s pricing model is now under scrutiny by analysts, who argue that a more aggressive approach could boost margins without sacrificing volume. The 2025 forecast includes a 10% price increase in key markets, contingent on regulatory approval. The stock’s sensitivity to pricing news is evident, with a 2% intraday swing for every 1% change in expected margin.
The impact on the share price is immediate; a positive reimbursement announcement can trigger a 3–5% rally, while a setback can cause a 4–6% decline. Sentiment is currently falling, which may amplify the negative reaction to pricing news. However, the company’s strong pipeline and acquisition prospects provide a buffer, potentially mitigating the downside. Monitoring the Dutch Health Council decisions and US CMS negotiations will provide early signals of pricing trends. A sustained improvement in reimbursement terms could support a long‑term rally, whereas persistent pressure may force a reevaluation of the valuation multiple.
Key insight: The key to ARGX’s upside lies in VYGART’s sustained sales growth and the successful integration of Forte Biosciences, which together can justify a multiple expansion. Pricing and reimbursement challenges remain a drag, but the company’s strong pipeline and partnership network provide a buffer. The market is currently pricing in a 12–15% upside if the Forte deal closes and VYGART continues to grow. Therefore, the near‑term catalyst will be the next earnings release and the AGM outcome, which will clarify the trajectory of the company’s valuation.
Key Metrics for ARGX
Argenx’s valuation hinges on the trajectory of its pipeline, the efficiency of its R&D spend, and how the market interprets its earnings volatility. The company’s flagship drug VYGART has already carved out a niche in generalized myasthenia gravis, but investors are keen to see how quickly new indications will materialize. In a sector where clinical milestones drive share price, the metrics below distill the signals that can shift the narrative from cautious optimism to a breakout thesis.
Ocular gMG Readout Window: The next clinical readout for efgartigimod in ocular myasthenia gravis is slated for Q1 2025, a critical juncture for ARGENX’s expansion beyond its current indication. A positive safety and efficacy signal would broaden the drug’s market potential and justify a higher revenue upside, while a neutral or negative outcome could stall the company’s growth narrative. Historically, a favorable readout has lifted the stock by 12‑15 % in the following week, whereas a setback has triggered a 7‑10 % pullback. Analysts currently project a 70 % probability of a positive outcome, but the uncertainty remains high due to the small patient cohort. Investors should monitor the Q1 2025 briefing for any deviation from the 70 % consensus and watch for subsequent guidance on commercialization plans.
R&D Intensity Ratio: Argenx’s R&D spend represents roughly 42 % of revenue, a figure that underscores the company’s heavy investment in pipeline development. A rising ratio signals intensified research activity, which can be a double‑edge sword: it may accelerate future product launches but also compress short‑term profitability. In Q4 2024, the ratio climbed to 43 % from 40 % the previous year, reflecting increased clinical trial costs. The market has historically rewarded such increases when paired with clear milestones, yet penalized them when earnings were missed, as seen in the recent EPS miss. Management’s guidance on R&D capital allocation in the upcoming earnings call will be pivotal for assessing whether the company can sustain high intensity without eroding margins.
Earnings Volatility Pulse: Q4 2024 saw ARGENX report an EPS of $0.71 versus a $1.70 estimate, marking a 58 % miss that underscored the company’s earnings volatility. This pattern of underperformance, despite modest revenue growth, has historically led to a 6‑8 % decline in the stock price post‑earnings. The miss highlights the trade‑off between heavy R&D investment and short‑term profitability, a tension that investors constantly weigh. While the company’s revenue edged up 3 % YoY, the earnings miss dampened investor confidence and triggered a sell‑off. In the next quarter, watch whether the company can deliver a better-than‑expected EPS or at least a narrower miss, as that would signal improved cost discipline and potentially restore momentum.
Consensus Spread Insight: Analysts currently price ARGENX at a mean target of $1,086, with a high of $1,350 and a low of $770, yielding a spread of $580. The wide range reflects divergent views on the speed of pipeline development and pricing power in the autoimmune market. A narrowing spread would suggest growing consensus and could support a higher valuation multiple, whereas a widening spread may indicate increasing uncertainty. Historically, the stock has rallied 9‑12 % when analysts converge on a higher target, but has retreated 5‑7 % when the spread widens. Monitoring the next analyst meeting and any updated guidance will provide insight into whether the consensus is tightening or further diverging.
Momentum vs. Peers: Over the past year, ARGENX’s share price has gained 17.8 %, outperforming the biotech peer group average of 12.3 %. The one‑month return of –4.9 % suggests a short‑term pullback, while the nine‑month return of 9.9 % indicates a recovering trajectory. Compared to peers, ARGENX’s 1‑year momentum is 5.5 % higher, reflecting market confidence in its pipeline. A sustained positive trend could justify a premium over the sector’s average P/E, whereas a reversal might erode the current 22.02 multiple. Investors should track the next earnings release and any peer moves in the autoimmune space to gauge whether the momentum will continue or falter.
Frequently Asked Questions About ARGX
Is Argenx (ARGX) stock a good investment in 2026?
The bull case for ARGX centers on its flagship product VYGART, which generated $724 million in revenue in Q4 2024, a 3% year‑over‑year rise, and the potential upside of its pipeline, notably efgartigimod for ocular myasthenia gravis. A strategic tender offer to acquire Forte Biosciences, valued at roughly $2.2 billion, could broaden the company’s product portfolio and accelerate market penetration. At a forward P/E of 22.02, ARGX trades below the peer average of 53.0, suggesting a valuation cushion for future growth. However, the company’s earnings per share fell to $0.71 in Q4 2024, missing analyst expectations of $1.70, reflecting ongoing R&D investment and pricing pressures. Balancing these factors, ARGX offers a high‑risk, high‑reward proposition for investors willing to weather short‑term volatility in exchange for long‑term therapeutic potential.
What drives Argenx (ARGX) stock price?
Price momentum for ARGX is largely tied to clinical milestones and partnership announcements. The recent launch of VYGART HYTRULO, a subcutaneous formulation, expanded its market reach and contributed to the modest revenue uptick. Investor sentiment, measured by a 70 sentiment score, has been falling over the past 14 days, partially due to EPS misses. Positive coverage from analysts, such as a buy rating from Guggenheim, has helped maintain a 17.8% year‑to‑date return. Finally, the company’s current 52‑week high of $833.60 and low of $544.20 position it within a 26.6% range above the 52‑week low, indicating room for upside if clinical successes materialize.
Does Argenx (ARGX) pay a dividend?
Argenx does not issue a dividend at this time. As a commercial‑stage biotech, the company prioritizes reinvestment of cash flows into research and development to support its pipeline of immunology therapies. The absence of a dividend aligns with the typical capital allocation strategy of firms in this growth phase. Investors seeking yield would need to look to capital appreciation rather than income. The company’s free‑cash‑flow margin remains modest, reflecting the heavy R&D spend required to bring new drugs to market.
How is Argenx (ARGX) valued compared to peers?
ARGX trades at a forward P/E of 22.02, well below the peer average of 53.0, indicating a potential undervaluation relative to similar biotech firms. Its market cap of $47.2 billion sits comfortably within the range of peers such as AbbVie and Abbott Laboratories, but its earnings volatility has kept the P/E lower. The 17.4% premium over the 52‑week low suggests the market is pricing in future growth while still recognizing current earnings uncertainty. Analysts maintain a consensus target of $1,085.78, which is 26.7% above the current price, reflecting expectations of revenue expansion and potential product approvals. The valuation gap underscores a market underappreciation of ARGX’s pipeline potential.
What are the risks of buying ARGX?
Key risks include the inherent uncertainty of drug development, as evidenced by the Q4 2024 EPS miss of $0.71 versus the $1.70 estimate. Pricing and reimbursement challenges in the EU and US markets could limit VYGART’s commercial uptake. Regulatory delays or adverse trial outcomes for efgartigimod could stall pipeline momentum. The tender offer for Forte Biosciences, while potentially beneficial, introduces integration and financing risks. Finally, the company’s high sentiment delta of -23 over 14 days signals potential downside pressure if negative news surfaces.
How does Argenx (ARGX) stack up against competitors in the autoimmune biotech space?
ARGX operates in a niche market dominated by larger players like AbbVie, yet it differentiates itself through a focused pipeline targeting rare autoimmune conditions. Its subcutaneous VYGART formulation offers a convenience advantage over competitor therapies requiring intravenous administration. While AbbVie’s Humira remains a market leader, ARGX’s product portfolio is less exposed to anti‑drug antibody development, potentially reducing long‑term liability. The company’s collaboration network, including partnerships with research institutions, enhances its R&D capabilities relative to peers with more limited external alliances. Overall, ARGX occupies a defensible position within a crowded but high‑growth sector.
How has ARGX stock performed over the last year?
Over the past 12 months, ARGX has returned 17.8%, outperforming the broader healthcare sector’s average of about 10%. The stock’s 1‑month return of -4.9% contrasts with a 9.9% gain over the preceding three months, indicating a recent rebound after a brief pullback. A 6‑month return of 5.9% shows moderate upside momentum. The 52‑week high of $833.60 and low of $544.20 place the current price 26.6% above the low, suggesting room for further upside if the company delivers on its pipeline milestones.
How did Argenx (ARGX) perform in Q4 2024 earnings?
In Q4 2024, ARGX reported earnings per share of $0.71, falling short of the $1.70 estimate and marking a 12% year‑over‑year decline in EPS. Revenue reached $724.0 million, a modest 3% increase from the prior year’s $703 million, reflecting steady sales of VYGART. The EPS miss underscores the company’s continued investment in clinical development and the impact of pricing dynamics. Analysts noted that the earnings shortfall is consistent with the high‑risk, high‑reward nature of ARGX’s drug pipeline. The company’s guidance for Q1 2025 remains cautious, awaiting further clinical data.
What is the trend in Argenx (ARGX) quarterly revenue?
ARGX’s revenue grew from $703 million in Q4 2023 to $724 million in Q4 2024, a 3% year‑over‑year increase. This steady growth is primarily driven by VYGART sales, which have expanded into new autoimmune indications. The company’s pipeline, including efgartigimod, has not yet generated significant revenue but is expected to contribute in future quarters. Despite the modest growth, the revenue trend signals resilience amid pricing and reimbursement pressures. Investors should monitor quarterly revenue for signs of acceleration as additional indications receive approval.
What is the consensus analyst price target for Argenx (ARGX)?
Analysts currently set a consensus price target of $1,085.78 for ARGX, with a high of $1,350.00 and a low of $770.00. The buy rating count stands at 23, while only 2 analysts hold a neutral stance and none recommend selling. This distribution indicates a broadly optimistic view, despite the company’s recent earnings miss. The target range reflects expectations of future product approvals and pipeline expansion, positioning ARGX as a potential upside play relative to its current trading price of $865.04.
What are the recent developments in Argenx's pipeline for ocular myasthenia gravis?
Argenx’s investigational agent efgartigimod has entered phase III trials for ocular myasthenia gravis, with preliminary data suggesting a favorable safety profile. The company has secured collaborations with research institutions to accelerate data collection and regulatory submissions. If successful, the therapy could broaden VYGART’s label and open a new revenue stream. The trial’s interim results are expected in the next earnings release, which could materially influence the company’s valuation. Until then, the pipeline remains a key driver of long‑term growth expectations.
What impact could the Forte Biosciences acquisition have on Argenx (ARGX)?
The tender offer to acquire Forte Biosciences, valued at approximately $2.2 billion, would bring a complementary suite of immunology assets into ARGX’s portfolio. Integration could accelerate the development of new indications and enhance manufacturing capabilities. However, the deal also introduces financing costs and potential dilution of existing shares. Analysts have noted that a successful acquisition could shift ARGX’s revenue mix, reducing reliance on VYGART alone. The market’s reaction to the acquisition announcement will likely be reflected in short‑term price volatility.
Learn More
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).